Mark Quick

Executive Vice President – Corporate Development, is responsible for leading Recipharm’s merger and acquisition (M&A) activities. He also leads Recipharm’s external and internal communications activities. With over 20 years of experience in the pharmaceutical contract development and manufacturing industry in supply chain and business development roles Mark also holds an MBA.

Latest articles

Maxwellia makes two new appointments

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
BMS & Boston Medical Center enter collaboration

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...